CD33 and acute myeloid leukemia: On September 17, 2017, the FDA approved the use of GO for patients newly diagnosed with CD33-positive acute lymphoblastic leukemia (ALL) and those who had relapsed or refractory CD33-positive AML based on results from three clinical trials (ALFA-0701 [95], AML-19 [96], and MyloFrance-1 [97]).